SubscribeEvents calendarAdvertiseNewsfeedContactLegal noticePrivacy Policy
Tobacco Journal International
Newsletter
Events calendar     Search archive for in
Login

Username:

Password:

Forgot your password?

Get a password

Newsletter

 
SWITZERLAND

PMI appoints new Chief Life Sciences Officer

12 Jan 2021. In its mission to deliver a smoke-free future, Philip Morris International (PMI) has brought on Jorge Insuasty as new Chief Life Sciences Officer, according to a company press release.

Mr. Insuasty, who holds an MD in cardiology from the University of Paris, joins PMI from Sanofi S.A., where he was the Global Franchise Head of Immunology, Oncology, and Neurology for Sanofi Genzyme. During his nine-year tenure at Sanofi he led the company’s product pipeline strategy with a dozen novel drugs approved. Prior to that, Mr. Insuasty spent eight years at Novartis International AG as Global Head of Development, Neuroscience, and Ophthalmology, states the press release.

“I am very excited to join PMI,” said Insuasty. “The company’s transformation, and smoke-free vision represent a tremendous public health opportunity and a business challenge, both of which I will be thrilled to contribute toward. And I also look forward to developing adjacent future growth drivers.”

Mr. Insuasty will replace the current Chief Life Sciences Officer John O’Mullane who is retiring and will report to the company’s CEO, André Calantzopoulos.

“Jorge’s wealth of experience across both the pharmaceutical and consumer healthcare industries makes him the ideal candidate to succeed John O’Mullane, who is retiring,” said Calantzopoulos. “Jorge is a transformational leader in science and medicine and excels in driving product portfolio development through to market success. Science and a consumer-focused product portfolio are the cornerstones of our ambition to replace cigarettes with products that are a better choice than continued smoking. Jorge’s impressive track record will help ensure we reach our goals and take full advantage of adjacent revenue-generating opportunities.”

“We thank John for the enormous contributions he has made these last two years, driving innovation and rigor into our life sciences function, and we wish him well in his retirement,” added Calantzopoulos.